Neptune Reports Net Profit for the Second Quarter

Laval, Québec, CANADA – October 15, 2010 – Neptune Technologies & Bioressources Inc. (“Neptune”) (NASDAQ.NEPT - TSX.V.NTB) today reports its consolidated financial results for the three and six-month periods ended August 31, 2010.

• Revenue increased by 200% to $4,114,000 for the three-month period ended August 31, 2010, up from $1,371,000 achieved during the corresponding period ended August 31, 2009.
• Consolidated EBITDA for the three-month period ended August 31, 2010 amounted to $732,000, compared to negative $(1,634,000) obtained during the corresponding period ended August 31, 2009.
• Net earnings increased by $2,386,000 and net income reached $274,000, or $0.01 per share for the three-month period ended August 31, 2010, compared to a net loss of $(2,112,000), or $(0.06) per share, for the corresponding period ended August 31, 2009.

• Nutraceutical revenue increased by 204% to $4,109,000, for the three-month period ended August 31, 2010, up from $1,352,000 achieved during the corresponding period ended August 31, 2009.
• EBITDA from nutraceutical business for the three-month period ended August 31, 2010 amounted to $1,207,000, compared to a negative $(997,000) obtained during the corresponding period ended August 31, 2009.
• Earnings from nutraceutical business increased by $2,285,000 net income reached $794,000 for the three-month period ended August 31, 2010, compared to a net loss of $(1,491,000), for the corresponding period ended August 31, 2009.

• Revenue increased by 95% to $8,276,000 for the six-month period ended August 31, 2010, up from $4,248,000 achieved during the corresponding period ended August 31, 2009.
• Consolidated EBITDA for the six-month period ended August 31, 2010 amounted to $1,408,000, compared to a negative $(1,917,000) obtained during the corresponding period ended August 31, 2009.
• Net earnings increased by $4,269,000 and net income reached $750,000, or $0.02 per share for the six-month period ended August 31, 2010, compared to a net loss of $(3,519,000), or $(0.09) per share, for the corresponding period ended August 31, 2009.

• Nutraceutical revenue increased by 96% to $8,266,000, for the six-month period ended August 31, 2010, up from $4,211,000 achieved during the corresponding period ended August 31, 2009.
• EBITDA from nutraceutical business for the six-month period ended August 31, 2010 was $2,303,000, compared to a negative $(962,000) obtained during the corresponding period ended August 31, 2010.
• Earnings from nutraceutical business improved by $4,246,000 and net income reached $1,692,000 for the six-month period ended August 31, 2010, compared to a net loss of $(2,554,000), for the corresponding period ended August 31, 2009.

About Neptune Technologies & Bioressources Inc.

Neptune is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipid products for the nutraceutical and pharmaceutical markets. The Company focuses on growing consumer health markets including cardiovascular, inflammatory and neurological diseases driven by consumers taking a more proactive approach to managing health and preventing disease. The Company sponsors clinical trials aimed to demonstrate its product health benefits and to obtain regulatory approval for label health claims. Neptune is continuously expanding its intellectual property portfolio as well as clinical studies and regulatory approvals. Neptune’s products are marketed and distributed in over 20 countries worldwide.

About Acasti Pharma Inc.

Acasti Pharma is developing a product portfolio of proprietary novel long-chain omega-3 phospholipids. Phospholipids are the major component of cell membranes and are essential for all vital cell processes. They are one of the principal constituents of High Density Lipoprotein (good cholesterol) and, as such, play an important role in modulating cholesterol efflux. Acasti Pharma’s proprietary novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have substantial health benefits and which are stabilized by potent antioxidants. Acasti Pharma is focusing initially on treatments for chronic cardiovascular conditions within the over-the-counter, medical food and prescription drug markets.

About NeuroBioPharm

NeuroBioPharm is pursuing pharmaceutical neurological applications, and a clinical study for a medical food product with a multinational partner is already initiated. The development of a prescription drug candidate is currently in progress. Advanced clinical development and commercialization is planned to be carried out with multinational partners.

"Neither Nasdaq nor the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."